^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
Published date:
04/09/2020
Excerpt:
As of June 1, 2017, the objective response rate among patients with PD-L1 TC ≥25% was 35.6%, 34.4%, and 37.7% with durvalumab, durvalumab plus tremelimumab, and chemotherapy, respectively (eTable 7 in Supplement 1).
DOI:
10.1001/jamaoncol.2020.0237
Trial ID:
Source:
Title:
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer?
Published date:
03/24/2020
Excerpt:
In heavily pretreated patients with mNSCLC, durvalumab demonstrated clinically meaningful improvements in OS and PFS versus SoC (patients with PD-L1 TC ≥25%); numerical improvements in OS and PFS for durvalumab + tremelimumab versus SoC were observed (patients with PD-L1 TC <25%).
DOI:
https://doi.org/10.1016/j.annonc.2020.02.006
Trial ID:
Source:
Title:
Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Excerpt:
......
Trial ID:
More C2 evidence
Source:
Title:
Phase II Study: Second line therapy in patients with non small cell lung cancer (NSCLC) with Durvalumab plus Tremelimumab after platinum based chemotherapie compared with platinum based chemotherapy alone Phase II Studie: Zweitlinientherapie in Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Durvalumab plus Tremelimumab nach Platinum-basierter Chemotherapie verglichen mit alleiniger Platinum-basierter Chemotherapie
Excerpt:
...Documented tumor PD-L1 expression status of ≥50%. ...
Trial ID:
